ALISKIREN - NEW DATA OF EVIDENCE-BASED MEDICINE AND PROSPECTS OF APPLICATION.


M.V. Leonova

SBEI HPE RNSMU n.a. N.I. Pirogov of RMPH, Moscow
The article presents the review of new scientific data on the mechanism of action of a direct renin inhibitor - aliskiren, and the difference of its impact on the basic components of the renin-angiotensin-aldosterone system (RAAS) in comparison to other RAAS blockers. New data of meta-analyses of the efficacy and safety of aliskiren are discussed. Meta-analyses have shown comparable efficacy and tolerability of aliskiren with angiotensin receptor antagonists and other antihypertensive drugs. Long-term studies on the organoprotective effects of aliskiren suggest the achievement of regression of left ventricular hypertrophy in patients with arterial hypertension and proteinuria in patients with arterial hypertension and diabetic nephropathy; there was no increased risk of total and cardiovascular mortality. Evaluation of possible use of aliskiren in other cardiovascular disease showed no benefits of the drug to the existing ones.

Literature


  1. Schmieder R.E., Hilgers K.F., Schlaich M.P., Schmidt B.M.W. Renin-angiotensin system and cadiovascular risk. Lancet. 2007;369:1208–19.
  2. Mentz R.J., Bakris G.L., Waeber B., McMurray J.J., Gheorghiade M., Ruilope L.M., Maggioni A.P., Swedberg K., Pina I.L., Fiuzat M., O’Connor C.M., Zannad F., Pitt B. The past, present and future of renin–angiotensin aldosterone system inhibition. Int. J. Cardiol. 2013;167(5):1677–87.
  3. Maibaum J., Feldman D.L. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin. Ther. Patents. 2003;13:589–603.
  4. Allikmets K. Aliskiren – an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. Vasc. Health Risk Manag. 2007:3(6) 809–15.
  5. Alreja G., Joseph J. Renin and cardiovascular disease: Worn-out path, or new direction? World J. Cardiol. 2011;3(3):72-83.
  6. Ferrario C.M. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47;515–21.
  7. Rajagopalan S., Bakris G.L., Abraham W.T., et al. Complete renin–angiotensin–aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013;62:444–49.
  8. Weir M.R., Bush C., Anderson D.R., Zhang J, Keefe D., Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J. Am. Soc. Hypertens. 2007;1:264–77.
  9. Zheng Z., Shi H., Jia J., Li D., Lin S. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension. JRAAS. 2010;12(2):102–12.
  10. Gao D., Ning N., Niu X., Wei J., Sun P., Hao G. Aliskiren vs. аngiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. Am. J. Hypert. 2011;24(5):613–21.
  11. Chen Y., Meng L., Shao H., Yu F. Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. Hypertens. Res. 2013;36(3):252–61.
  12. Sealey J.E., Laragh J.H. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am. J. Hypertens. 2007;20:587–97.
  13. Stanton A.V., Gradman A.H., Schmieder R.E., et al. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 linical trials. Hypertension. 2010;55:54–60.
  14. Sen S., Sabırlı S., Ozyigit T., Uresin Y. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. Ther Adv Chronic Dis. 2013;4(5): 232–41.
  15. Pouleur A.С., Uno H., Prescott M.F., Desai A. (for the ALLAY Investigators). Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. JRAAS. 2011;12:483–90.
  16. Parving H.H., Persson F., Lewis J.B., et al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2008;358:2433–46.
  17. Kelly D.J., Zhang Y., Moe G., Naik G., Gilbert R.E. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50:2398–404.
  18. Duprez D.A., Davis P., Botha J. The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients >65 years of age with systolic hypertension. Circulation. 2008;118:S886–87.
  19. McMurray J.J.V., Pitt B., Latini R., et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 2008;1:17–24.
  20. Scirica B., Morrow D., Bode C., Ruzyllo W., Ruda M., Oude Ophuis A.J., Lopez-Sendon J., Swedberg K., Ogorek M., Rifai N., Lukashevich V., Maboudian M., Cannon C.P., McCabe C.H., Braunwald E. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43Trial. Eur. Heart J. 2010;31:1993–2005.
  21. Solomon S., Sung H., Shah A., Skali H., Desai A., Kober L., Maggioni A.P., Rouleau J.L., Kelly R.Y., Hester A., McMurray J.J., Pfeffer M.A. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 2011;32:1227–34.
  22. Nicholls S.J., Bakris G.L., Kastelein J.J.P. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013;310(11):1135–44.
  23. White W.B., Bresalier R., Kaplan A.P., Palmer B.F., Riddell R.H., Lesogor A., Chang W., Keefe D.L. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J. Clin. Hypertens. (Greenwich) 2010;12:765–75.
  24. Harel Z., Gilbert C., Wald R., Bell C., Perl J., Juurlink D., Beyene J., Shah P.S.The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:1–12.
  25. Catala-Lopez F., Saint-Gerons D.M., Honrubiay C.F., Martin-Serrano G. Risks of dual blockade of the renin-angiotensin system compared with monotherapy: a systematic review and cumulative meta-analysis of randomized trials and observational studies. Rev. Esp. Salud Publica. 2014;88:37–65.


About the Autors


M.V. Leonova – Doctor of Medical Sciences, Prof., Corr. Member of Russian Academy of Natural Sciences, Prof. at the Department of Clinical Pharmacology SBEI HPE RNSMU n.a. N.I. Pirogov of RMPH, Moscow; e-mail: anti23@mail.ru


Similar Articles


Бионика Медиа